A preliminary study on the role of the complement regulatory protein, cluster of differentiation 55, in mice with diabetic neuropathic pain

Nie,Fachuan; Su,Dong; Shi,Ying; Chen,Jinmei; Wang,Haihui; Qin,Wanxiang; Chen,Yaohua; Wang,Suxia; Li,Lei

doi:10.3892/mmr.2014.2896

A preliminary study on the role of the complement regulatory protein, cluster of differentiation 55, in mice with diabetic neuropathic pain

Authors:
- Fachuan Nie
- Dong Su
- Ying Shi
- Jinmei Chen
- Haihui Wang
- Wanxiang Qin
- Yaohua Chen
- Suxia Wang
- Lei Li
View Affiliations

Affiliations: Department of Pain, The First Affiliated Hospital, Third Military Medical University, Chongqing 400038, P.R. China, Department of Anesthesiology, Women's and Children's Central Hospital, Chengdu, Sichuan 610031, P.R. China
Published online on: November 7, 2014 https://doi.org/10.3892/mmr.2014.2896
Pages: 2076-2082

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the role of the complement regulatory protein cluster of differentiation 55 (CD55) in the pathogenesis of diabetic neuropathic pain (DNP). Healthy adult male C57BL/6J mice were intraperitoneally injected with streptozotocin (STZ) in order to induce DNP. Peripheral blood glucose and protein, and the mRNA expression levels of C3 and CD55 in the spinal cord were determined. In addition, the behaviors of these mice were observed. The results showed that STZ‑treated mice displayed the clinical manifestations of diabetes mellitus, and that their peripheral blood glucose was markedly increased. On the 21st and 28th days following the STZ injection, the mechanical pain threshold and thermal pain threshold of the mice were dramatically reduced (P<0.05). |Additionally, 14 days post‑STZ injection, the mRNA expression of C3 in the spinal cord was significantly increased, which continued for 28 days. On the 21st and 28th days, the number of C3 positive cells in the spinal cord was markedly increased. Seven days after the STZ injection, the number of cells positive for CD55 was markedly reduced in the spinal dorsal horn and subsequently remained at a low level. The mRNA expression of CD55 also was significantly reduced (P<0.05) and remained so for 28 days. The reduction in the expression levels of CD55 occurred earlier than the changes in the expression of C3, suggesting that the downregulation of CD55 expression precedes, and has an important role regarding, the activation of C3 in the occurrence and development of DNP.

View Figures

View References

1	Kessler NJ and Hong J: Whole body vibration therapy for painful diabetic peripheral neuropathy: a pilot study. J Bodyw Mov Ther. 17:518–522. 2013. View Article : Google Scholar : PubMed/NCBI
2	Kalra B, Kalra S and Bajaj S: Vulvodynia: An unrecognized diabetic neuropathic syndrome. Indian J Endocrinol Metab. 17:787–789. 2013. View Article : Google Scholar : PubMed/NCBI
3	Nie F, Wang J, Su D, Shi Y, Chen J, Wang H, Qin W and Shi L: Abnormal activation of complement C3 in the spinal dorsal horn is closely associated with progression of neuropathic pain. Int J Mol Med. 31:1333–1342. 2013.PubMed/NCBI
4	Levin ME, Jin JG, Ji RR, Tong J, Pomonis JD, Lavery DJ, Miller SW and Chiang LW: Complement activation in the peripheral nervous system following the spinal nerve ligation model of neuropathic pain. Pain. 137:182–201. 2008. View Article : Google Scholar
5	Rosoklija GB, Dwork AJ, Younger DS, Karlikaya G, Latov N and Hays AP: Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol. 99:55–62. 2000. View Article : Google Scholar : PubMed/NCBI
6	Lalive PH, Truffert A, Magistris MR, Landis T and Dosso A: Peripheral autoimmune neuropathy assessed using corneal in vivo confocal microscopy. Arch Neurol. 66:403–405. 2009.PubMed/NCBI
7	Mamidi S, Cinci M, Hasmann M, Fehring V and Kirschfink M: Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol Oncol. 7:580–594. 2013. View Article : Google Scholar : PubMed/NCBI
8	Bani-Ahmad M, El-Amouri IS, Ko CM, Lin F, Tang-Feldman Y and Oakley OR: The role of decay accelerating factor in the immunopathogenesis of cytomegalovirus infection. Clin Exp Immunol. 163:199–206. 2011. View Article : Google Scholar :
9	Galeotti N, Maidecchi A, Mattoli L, Burico M and Ghelardini C: St. John’s Wort seed and feverfew flower extracts relieve painful diabetic neuropathy in a rat model of diabetes. Fitoterapia. 92:23–33. 2014. View Article : Google Scholar
10	Ikeda H, Ikegami M, Kai M, Ohsawa M and Kamei J: Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice. Neuroscience. 250:446–454. 2013. View Article : Google Scholar : PubMed/NCBI
11	Shukla M, Quirion R and Ma W: Reduced expression of pain mediators and pain sensitivity in amyloid precursor protein over-expressing CRND8 transgenic mice. Neuroscience. 250:92–101. 2013. View Article : Google Scholar : PubMed/NCBI
12	Murakami T, Kanchiku T, Suzuki H, Imajo Y, Yoshida Y, Nomura H, Cui D, Ishikawa T, Ikeda E and Taguchi T: Anti-interleukin-6 receptor antibody reduces neuropathic pain following spinal cord injury in mice. Exp Ther Med. 6:1194–1198. 2013.PubMed/NCBI
13	Bak EJ, Kim J, Jang S, Woo GH, Yoon HG, Yoo YJ and Cha JH: Gallic acid improves glucose tolerance and triglyceride concentration in diet-induced obesity mice. Scand J Clin Lab Invest. 73:607–614. 2013. View Article : Google Scholar : PubMed/NCBI
14	Schmitt J, Roderfeld M, Sabrane K, Zhang P, Tian Y, Mertens JC, Frei P, Stieger B, Weber A, Müllhaupt B, Roeb E and Geier A: Complement factor C5 deficiency significantly delays the progression of biliary fibrosis in bile duct-ligated mice. Biochem Biophys Res Commun. 418:445–450. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kato C, Kato A, Adachi K, Fujii E, Isobe K, Watanabe T, Ito T and Suzuki M: Expression of membrane complement regulatory proteins Crry and CD55 in normal rats. J Toxicol Pathol. 26:223–236. 2013. View Article : Google Scholar : PubMed/NCBI
16	Mishra J, Sahoo PK, Mohanty BR and Das A: Sequence information, ontogeny and tissue-specific expression of complement component C3 in Indian major carp, Labeo rohita (Hamilton). Indian J Exp Biol. 47:672–678. 2009.PubMed/NCBI
17	Zell S, Geis N, Rutz R, Schultz S, Giese T and Kirschfink M: Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol. 150:576–584. 2007. View Article : Google Scholar : PubMed/NCBI
18	Loo LS and McNamara JO: Impaired volume regulation is the mechanism of excitotoxic sensitization to complement. J Neurosci. 26:10177–10187. 2006. View Article : Google Scholar : PubMed/NCBI
19	Tegla CA, Cudrici C, Rus V, Ito T, Vlaicu S, Singh A and Rus H: Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival. J Neuroimmunol. 213:3–11. 2009. View Article : Google Scholar : PubMed/NCBI
20	Tender GC, Li YY and Cui JG: The role of nerve growth factor in neuropathic pain inhibition produced by resiniferatoxin treatment in the dorsal root ganglia. Neurosurgery. 73:158–166. 2013. View Article : Google Scholar : PubMed/NCBI
21	Sundaram B, Singhal K and Sandhir R: Ameliorating effect of chromium administration on hepatic glucose metabolism in streptozotocin-induced experimental diabetes. Biofactors. 38:59–68. 2012. View Article : Google Scholar : PubMed/NCBI
22	Pandey AK, Gupta PP and Lal VK: Preclinical evaluation of hypoglycemic activity of Ipomoea digitata tuber in streptozotocin-induced diabetic rats. J Basic Clin Physiol Pharmacol. 24:35–39. 2013. View Article : Google Scholar
23	Courteix C, Eschalier A and Lavarenne J: Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain. 53:81–88. 1993. View Article : Google Scholar : PubMed/NCBI
24	Suehiro K, Funao T, Fujimoto Y, Yamada T, Mori T and Nishikawa K: Relationship between noradrenaline release in the locus coeruleus and antiallodynic efficacy of analgesics in rats with painful diabetic neuropathy. Life Sci. 92:1138–1144. 2013. View Article : Google Scholar : PubMed/NCBI
25	Hsieh CC, Chou HS, Yang HR, Lin F, Bhatt S, Qin J, Wang L, Fung JJ, Qian S and Lu L: The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood. 121:1760–1768. 2013. View Article : Google Scholar : PubMed/NCBI
26	Berg A, Zelano J, Stephan A, Thams S, Barres BA, Pekny M, Pekna M and Cullheim S: Reduced removal of synaptic terminals from axotomized spinal motoneurons in the absence of complement C3. Exp Neurol. 237:8–17. 2012. View Article : Google Scholar : PubMed/NCBI
27	Mika J, Zychowska M, Popiolek-Barczyk K, Rojewska E and Przewlocka B: Importance of glial activation in neuropathic pain. Eur J Pharmacol. 716:106–119. 2013. View Article : Google Scholar : PubMed/NCBI
28	Doehring A, Geisslinger G and Lötsch J: Epigenetics in pain and analgesia: an imminent research field. Eur J Pain. 15:11–16. 2011. View Article : Google Scholar
29	Yamamoto H, Fara AF, Dasgupta P and Kemper C: CD46: the ‘multitasker’ of complement proteins. Int J Biochem Cell Biol. 45:2808–2820. 2013. View Article : Google Scholar : PubMed/NCBI
30	Nevo Y, Ben-Zeev B, Tabib A, Straussberg R, Anikster Y, Shorer Z, Fattal-Valevski A, Ta-Shma A, Aharoni S, Rabie M, Zenvirt S, Goldshmidt H, Fellig Y, Shaag A, Mevorach D and Elpeleg O: CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood. 121:129–135. 2013. View Article : Google Scholar
31	Margolles-Clark E, Jacques-Silva MC, Ganesan L, Umland O, Kenyon NS, Ricordi C, Berggren PO and Buchwald P: Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects. Biochem Pharmacol. 77:1236–1245. 2009. View Article : Google Scholar : PubMed/NCBI
32	Nowicki B and Nowicki S: DAF as a therapeutic target for steroid hormones: implications for host-pathogen interactions. Adv Exp Med Biol. 735:83–96. 2013. View Article : Google Scholar : PubMed/NCBI
33	Lin F, Kaminski HJ, Conti-Fine BM, et al: Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest. 110:1269–1274. 2002. View Article : Google Scholar : PubMed/NCBI
34	Zhang J, Gerhardinger C and Lorenzi M: Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes. 51:3499–3504. 2002. View Article : Google Scholar : PubMed/NCBI